Type of non Hodgkin's lymphoma-Follicular lymphoma - Page 2 of 9 Posts on Medivizor
Navigation Menu

Type of non Hodgkin’s lymphoma-Follicular lymphoma Posts on Medivizor

Long-term outcomes of idelalisib treatment for patients with relapsed painless lymphoma

Long-term outcomes of idelalisib treatment for patients with relapsed painless lymphoma

Posted by on Jan 31, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study reported the long-term effectiveness and safety outcomes of treatment with idelalisib (Zydelig) after a longer follow-up of patients with indolent (painless) non-Hodgkin lymphoma. The data showed that idelalisib treatment improved the overall survival of these patients in the long-term. Some background Non-Hodgkin...

Read More

Effects of high-dose therapy and autologous hematopoietic stem cell transplantation for non-Hodgkin lymphoma in a resource-limited country

Effects of high-dose therapy and autologous hematopoietic stem cell transplantation for non-Hodgkin lymphoma in a resource-limited country

Posted by on Dec 6, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The study analyzed outcomes of high-dose therapy (HDT) with autologous hematopoietic stem cell transplantation (AHSCT) for patients with non-Hodgkin lymphoma (NHL) in a resource-limited country and evaluated whether upfront AHSCT could be an effective treatment. The authors found promising outcomes of this treatment in a resource-limited...

Read More

Evaluating zanubrutinib combined with obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma

Evaluating zanubrutinib combined with obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma

Posted by on Nov 2, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to investigate the combination of zanubrutinib (Brukinsa) and obinutuzumab (Gazyva) in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and follicular lymphoma (FL). This study concluded that this combination was well tolerated and had promising responses in these patients.  Some...

Read More

Seeking patients with relapsed B-cell NHL or CLL for trial of kinase-blocking treatment

Seeking patients with relapsed B-cell NHL or CLL for trial of kinase-blocking treatment

Posted by on Oct 11, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study will evaluate a three-drug regimen for the treatment of relapsed B-cell non-Hodgkin lymphoma (NHL) or chronic lymphocytic leukemia (CLL). The primary outcomes are how many patients respond to treatment or have a complete response (cancer no longer detectable). The study will take place in the United States. The details B-cell...

Read More

Looking for participants to test an experimental immunotherapy for relapsed non-Hodgkin lymphoma

Looking for participants to test an experimental immunotherapy for relapsed non-Hodgkin lymphoma

Posted by on Oct 11, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study will evaluate the antibody therapy odronextamab for patients with relapsed B-cell non-Hodgkin lymphoma (NHL). The primary outcomes will be how many patients respond to treatment, and how many have a complete response (cancer no longer detectable).  The details For B-cell NHL which has relapsed (returned) after...

Read More

Evaluating 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma

Evaluating 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma

Posted by on Oct 4, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The study evaluated the safety and effectiveness of 177Lu-lilotomab satetraxetan (177LLS; Betalutin) in patients with relapsed/refractory (r/r) indolent non-Hodgkin lymphoma (iNHL). The main finding was that 177LLS was proven to be a valuable alternative treatment in such patients. Some background NHL is a type of lymphoma that spreads...

Read More

Axicabtagene ciloleucel for aggressive B-cell lymphoma outside clinical trials

Axicabtagene ciloleucel for aggressive B-cell lymphoma outside clinical trials

Posted by on Jul 28, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study looked at axicabtagene ciloleucel (Yescarta) to treat B-cell non-Hodgkin lymphoma which has returned after previous treatment outside of clinical trials. It found that most patients responded to this immune therapy and that some patients had a complete response. Some background B-cell non-Hodgkin lymphomas (NHL) are a group of...

Read More

How does COVID-19 affect patients with cancer undergoing chemotherapy?

How does COVID-19 affect patients with cancer undergoing chemotherapy?

Posted by on Jun 21, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study examined how COVID-19 infection affects patients with cancer undergoing chemotherapy and the role of other factors in COVID-19 complications. The results showed that patients with advanced age and other medical conditions had a higher risk of COVID-19 complications but chemotherapy treatment did not need to be stopped. Some...

Read More

Which targeted therapy leads to the best quality of life for advanced FL?

Which targeted therapy leads to the best quality of life for advanced FL?

Posted by on May 30, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study looked at the quality of life for patients with advanced follicular lymphoma (FL) who were treated with obinutuzumab (Gazyva) and chemotherapy compared to those treated with rituximab (Rituxan) and chemotherapy. It found that both targeted antibody therapies improved quality of life for patients with advanced FL. Some background...

Read More

Higher or lower radiotherapy dose for patients with non-Hodgkin lymphoma undergoing stem cell transplantation?

Higher or lower radiotherapy dose for patients with non-Hodgkin lymphoma undergoing stem cell transplantation?

Posted by on May 26, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study examined how effective and safe a higher radiotherapy dose was for patients with non-Hodgkin lymphoma (NHL) undergoing stem cell transplantation (SCT). The authors found that patients who received a lower radiotherapy dose survived longer and had fewer side effects than the higher dose. Some background NHL is a cancer of...

Read More